Saturday 17 October 2026
Export GRAL’s income statement to Excel — free account
GRAIL, Inc.
GRAL Healthcare Diagnostics & Research
GRAIL, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $147.2 million, up 17.2% from fiscal 2024. In the quarter to June 2026, revenue grew 25.7%, EPS grew 19.5% and free cash flow fell 4.95%, each against the same quarter a year earlier. Revenue growth for three consecutive years.
117.81
17.65
−13.03%
Follow GRAL
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
15.06 | 21.37 | 13.45 | 17.81 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(33.77) | (49.32) | (24.14) | (36.46) | |
P/B ratio |
0.95 | 1.22 | 0.84 | 1.16 | |
Price to Tangible BV |
6.02 | 4.33 | 3.07 | 3.87 | |
EV/Sales |
11.25 | 15.23 | 8.18 | 12.60 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(4.85) | (7.50) | (4.39) | (7.06) | |
EV/FCF |
(4.84) | (7.47) | (4.37) | (7.03) | |
Quick Ratio |
7.19 | 11.58 | 11.29 | 10.55 | |
Current Ratio |
7.61 | 11.97 | 11.74 | 10.95 | |
Net Debt/EBITDA |
5.93 | 10.04 | 7.95 | 7.44 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.05 | 0.05 | 0.06 | 0.06 | |
Operating CF/Net income |
0.71 | 0.64 | 0.93 | 0.73 | |
Capex/Depreciation |
(0.01) | 0.00 | (0.02) | (0.01) | |
Research and Development Expense of Revenue |
134.41% | 107.57% | 117.74% | 106.14% | |
Selling, General and Administrative Expense of Revenue |
173.82% | 152.26% | 180.06% | 197.74% | |
Intangible Assets out of Total Assets |
0.72 | 0.63 | 0.65 | 0.63 | |
Share Based Compensation of Revenue |
39.06% | 31.57% | 41.17% | 43.76% | |
Graham Net Nets |
0.11 | 0.19 | 0.27 | 0.21 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(19.67%) | (13.06%) | (20.07%) | (14.28%) | |
Free Cash Flow Yield |
(15.44%) | (9.53%) | (13.92%) | (10.06%) | |
Revenue per Share |
1.00 | 1.19 | 1.00 | 1.04 | |
Operating CF per Share |
(1.75) | (1.74) | (2.14) | (1.87) | |
Capex per Share |
(0.01) | 0.00 | (0.01) | (0.01) | |
Free Cash Flow per Share |
(1.76) | (1.74) | (2.15) | (1.88) | |
Cash per Share |
14.95 | 24.61 | 20.25 | 19.98 | |
Shareholders Equity per Share |
62.01 | 70.14 | 61.53 | 58.98 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
62.01 | 70.14 | 61.53 | 58.98 | |
Free Cash Flow |
(63.63) | (63.88) | (87.49) | (81.16) | |
Working Capital |
511.95 | 874.18 | 802.64 | 831.18 | |
Capital Expenditures |
(0.38) | (0.09) | (0.50) | (0.43) | |
Net Current Asset Value |
228.31 | 609.70 | 574.56 | 613.69 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | 0.00 | 0.01 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
15.75 | 19.30 | 19.83 | 18.04 | |
Average Payables |
5.36 | 3.46 | 5.22 | 6.76 | |
Average Assets |
2,859.49 | 2,952.66 | 2,825.54 | 2,773.12 | |
Average Common Equity |
2,413.80 | 2,540.63 | 2,457.18 | 2,428.65 |
Columns are period end dates